Skip To Main Content
This website is intended exclusively for the Registered Medical Practitioners in India.
Campus
Campus

IN UNCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS

 

DUPIXENT demonstrated rapid and sustained results in adults

and avoids broad immunosuppression1,2

It is unknown if DUPIXENT will influence the immune response against helminth infections
Demonstrated safety profile in adult patients1

About Dupixent®

Adult Safety Profile

Adult Safety Profile

Read article
Adult Real-World Results

AD Disease Severity and Persistency l Real-World Study Design

Read article
Real Patient Stories

Atopic Dermatitis: Real AD Patient Reports

Read article
Identifying Patients

Patient Case Studies

Read article
MOA: Mechanism of Action

MOA: Mechanism of Action

Read article
Frequently Asked Questions

Frequently Asked Questions l Dupilumab - FAQs

Read article

Efficacy and Safety

Adult EASI Efficacy Results

Dupilumab EASI Score Results l Dupixent Efficacy in Adults l AD

Read article
Adult IGA Efficacy Results

Adult IGA Efficacy Results

Read article
Adult Peak Pruritus NRS Efficacy Results

Adult Peak Pruritis NRS Efficacy Results

Read article
Adult (18+ Years) Study Designs

Adult Clinical Study Designs l Dupilumab Pivotal Trials

Read article

Dosage and Administration

Dosage and Administration

How to Inject l Dosage Regimen and Administration

Read article

Resources

Resource Library

Resource Library

Read article

To know more about DUPIXENT and it’s availability in India, please reach out to: Medinfo.India@sanofi.com / 1800 22 2295 (toll-free)

References

  1. DUPIXENT Prescribing Information.
  2. Data on file, Regeneron Pharmaceuticals, Inc.

Disclaimer: Patient images depicted here are fictitious and meant for illustrative purpose only. Any resemblance to any person, living or dead is purely coincidental.